School of Pharmacy, University of Reading, Whiteknights Campus, Reading, UK.
Department of Pharmacy, University of Reading, PO Box 226, Whiteknights, Reading, Berkshire, RG6 6AP, UK.
Support Care Cancer. 2020 Nov;28(11):5075-5084. doi: 10.1007/s00520-020-05585-9. Epub 2020 Jun 29.
Numerous studies have examined non-adherence to adjuvant endocrine therapy in women recovering from breast cancer, but none provides a comprehensive theory to explain the challenges of long-term medication taking and resilience needed to continue. The aim of this study was to source, appraise, and synthesize data from existing qualitative studies to develop an in-depth explanatory model of non-adherence and discontinuation of hormonal medication among breast cancer survivors.
A comprehensive search of databases and the literature identified 24 eligible qualitative studies published 2010-2019. Quotations (n = 801) listed within these papers and the original author interpretations were synthesized using NVivo, and grounded theory methodology.
At the beginning, knowledge about adjuvant endocrine therapy, trust in doctors, and worries and expectations, mean agreeing to medication is the only viable option, akin to a Hobson's choice. Thereafter, women's ability to deal with medication side-effects, knowledge and support received affect their decision to continue, akin to a horned dilemma where giving up the medication risks cancer recurrence and continuing means reduced contentment. Women stopping medication altogether question treatment necessity, search for normalcy and prioritize quality of life.
Shared experiences and understandings were uncovered by examining commonalities in existing publications. The core category explained the difficulties women face with the initial decision to accept long-term endocrine therapy and then the everyday challenges of continuing or deciding to stop treatment early. An educational tool to inform survivors and health professionals about these challenges could potentially improve women's experience on treatment and in turn their adherence.
许多研究都调查了乳腺癌康复女性对辅助内分泌治疗的不依从性,但没有任何研究提供全面的理论来解释长期服药的挑战和继续服药所需的韧性。本研究旨在从现有的定性研究中获取、评估和综合数据,以深入了解乳腺癌幸存者激素药物不依从和停药的原因。
全面检索数据库和文献,确定了 2010 年至 2019 年发表的 24 项合格的定性研究。对这些论文中列出的引文(n=801)和原始作者的解释使用 NVivo 进行了综合,并采用扎根理论方法。
一开始,对辅助内分泌治疗的了解、对医生的信任以及担忧和期望,意味着同意服药是唯一可行的选择,就像别无选择的选择。此后,女性处理药物副作用的能力、获得的知识和支持,会影响她们继续服药的决定,就像一个棘手的两难选择,放弃药物治疗意味着癌症复发的风险增加,而继续治疗则意味着满足感降低。完全停止服药的女性会质疑治疗的必要性,寻求正常生活,并优先考虑生活质量。
通过检查现有出版物中的共同点,揭示了共同的经验和理解。核心类别解释了女性在最初决定接受长期内分泌治疗时所面临的困难,以及在继续治疗或决定提前停止治疗时所面临的日常挑战。一个告知幸存者和卫生专业人员这些挑战的教育工具,有可能改善女性的治疗体验,并提高她们的依从性。